Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

1. Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026
   Review
2. Insights into Ovarian Cancer: Unraveling the Role of DNA Double-strand Break-related Genes in Pathogenesis and Therapeutic Avenues.Reproductive sciences (Thousand Oaks, Calif.) · 2026
   Review
3. Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.Journal of clinical medicine · 2026
   Review
4. The role of cytokines in ovarian cancer drug resistance.International journal of cancer · 2026
   Review
5. ATP attenuates olaparib-induced gastric damage in rats.Frontiers in pharmacology · 2026
   Article
6. Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis.Journal of gynecologic oncology · 2025
   Article
7. A rare presentation of high-grade serous ovarian carcinoma with ulcerating inguinal lymph node metastasis: a case report.Journal of surgical case reports · 2025
   Article
8. Evaluation of Different Commercial Sealing Hemostatic Patches for Their Selection as Reservoirs for Localized Intraperitoneal Chemotherapy.ACS pharmacology & translational science · 2025
   Article
9. An overview of pyridazin-3(2Future medicinal chemistry · 2024
   Review
10. Report of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutation.Cureus · 2024
    Article
11. Emerging role of MYB transcription factors in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2024
    Review
12. Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.International journal of molecular sciences · 2023
    Article
13. Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.Targeted oncology · 2023
    Article
14. Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines.Oncology reports · 2023
    Article
15. Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells.Biomolecules · 2023
    Article
16. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.Diagnostics (Basel, Switzerland) · 2023
    Article
17. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade SerousCells · 2022
    Article
18. Neuroprotective Effects of PARP Inhibitors inCells · 2022
    Article
19. Natural phytochemicals prevent side effects inFrontiers in pharmacology · 2022
    Review
20. Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know?Cancer control : journal of the Moffitt Cancer Center
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as